Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- General Strategies in Biomarker Research
-
55 min
1. The proteomic revolution- Dr. Larry Gold
-
39 min
2. Lipid biomarkers: lipidomics of the macrophage and plasma lipidomes- Prof. Edward A. Dennis
- New Tools for Biomarker Research
-
38 min
-
31 min
-
59 min
5. Development of glyco-biomarkers using glycoproteomics technologies- Dr. Hisashi Narimatsu
-
32 min
6. Circulating nucleic acids as biomarkers in cancer patients- Prof. Klaus Pantel
- Specific Disease Applications
-
28 min
7. Biomarkers in breast cancer- Prof. Joe Duffy
-
71 min
8. Bacterial biomarkers- Dr. Christiane Honisch
-
32 min
9. Diabetes biomarkers- Prof. Naveed Sattar
-
60 min
10. Gene networks, brain networks: understanding schizophrenia- Dr. Daniel Weinberger
-
29 min
11. Biomarkers for Huntington's disease - promises and challenges- Prof. Sarah Tabrizi
-
31 min
12. Update on fluid biomarkers for neurodegenerative diseases- Prof. Henrik Zetterberg
-
31 min
13. Biomarkers in osteoarthritis- Dr. Ali Mobasheri
- Biomarkers in Drug Discovery and Delivery
-
31 min
14. Pharmacogenomics: emphasis on clinical drug development- Dr. Amelia Warner
-
25 min
15. Biomarkers in drug development: potential use and challenges- Dr. Abdel-Bassett Halim
-
41 min
- Biomarkers in development, nutrition, and health
-
50 min
-
29 min
18. Ethnic differences in nutrition- Prof. Jose Ordovas
-
55 min
19. Non-invasive prenatal diagnostics- Prof. Y. M. Dennis Lo
-
44 min
20. Epigenetic biomarkers in cancer- Prof. Bob Brown
- Archived Lectures *These may not cover the latest advances in the field
-
23 min
21. Biomarkers for Alzheimer's disease- Prof. Henrik Zetterberg
Printable Handouts
Navigable Slide Index
- Introduction
- Presentation overview
- ICH E15 definitions
- Promise of genomics
- The complexity in predicting therapy
- What can the science do?
- Pharmacogenomic data impact
- Role of pharmacogenomics in patient outcomes
- Impact report
- Pharmacogenomics implementation barriers
- Opportunity of personalized medicine
- Falling costs of genomic technologies
- IL28B and peginterferon-a-2b treatment in HCV
- The research and development 'process'
- No increased productivity with advance in science
- Scientific challenges for pharma R&D
- Increasing shots on goal has not worked
- Reasons for phase 2 failures
- Getting the right medicine to the right patients
- Translational collaborations in drug discovery
- Why future use samples are useful
- Primary barriers to successful genetic research
- Risk/benefit
- Research scope
- Broad consent for future biomedical research
- Future vision
- Privacy protection
- Value proposition
- Getting closer to individualized therapy
- Identifiability of DNA
Topics Covered
- The promise of genomics
- The complexity in predicting therapy
- Pharmacogenomic data impact & implementation barriers
- Opportunity of personalized medicine
- Costs of genomic technologies and the research & development 'process'
- Scientific challenges for pharma R&D and primary barriers to successful genetic research
- Reasons for research failures
- Getting the right medicine to the right patients
- Translational collaborations in drug discovery
- Future biomedical research and vision while keeping privacy protection and value proposition in mind
Talk Citation
Warner, A. (2012, December 27). Pharmacogenomics: emphasis on clinical drug development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/CTIB1844.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Amelia Warner, Stock Shareholder (Self-managed): Merck
Pharmacogenomics: emphasis on clinical drug development
Published on December 27, 2012
31 min
